To the Editor In a multisite, randomized, phase 3, clinical trial, Dr Stupp and colleagues1 demonstrated a modest benefit for patients newly diagnosed with glioblastoma treated with tumor-treating fields (TTFields) and temozolomide vs temozolomide alone in progression-free survival (7.1 months for TTFields plus temozolomide vs 4 months for temozolomide alone) and overall survival (20.9 months for TTFields plus temozolomide vs 16 months for temozolomide alone). The authors should justify the current cost of the device ($20 000 per month) and also the discuss the effect on quality of life for both the patients (shaving their head) and family when patients wear the TTFields device 18 hours a day.
Kwan K, Schneider JR, Boockvar JA. Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields. JAMA. 2018;319(17):1822–1823. doi:10.1001/jama.2018.1858
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: